Therapeutic challenges and Emerging Strategies against Carbapenem-Resistant Acinetobacter baumannii
Highlights • Therapeutic Landscape Evolution : Current FDA-approved triple regimens feature sulbactam-durlobactam (SUL-DUR), the siderophore cephalosporin cefiderocol (FDC), and eravacycline. Zosurabalpin remains in Phase I evaluation, while Acinetobacter baumannii prophylactic vaccines are still undergoing preclinical development. • CRAB Treatment Paradigms : SUL-DUR combination therapy emerges as a promising first-line therapeutic candidate for critically ill patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. FDC demonstrates pivotal potential in multidrug-resistant pathogen co-therapy frameworks through its innovative iron-transport mechanism. • Strategic Interventions : Dual-track approaches are imperative: 1) Accelerating CRAB-targeted drug development through priority review pathways, implementing adaptive clinical trial designs, and establishing dynamic risk management-based post-marketing surveillance systems; 2) Strength...